Trial Outcomes & Findings for Garmin PACT (Physical Activity Tracking in Type 1 Diabetes Using Garmin Vivosmart) (NCT NCT05992350)

NCT ID: NCT05992350

Last Updated: 2025-10-17

Results Overview

Minutes per Day of MVPA

Recruitment status

TERMINATED

Target enrollment

45 participants

Primary outcome timeframe

Up to 365 days +- 30 days

Results posted on

2025-10-17

Participant Flow

Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).

Participant milestones

Participant milestones
Measure
Primary Analysis Arm
Youth (8-21 YO) diagnosed with T1D.
Parent Arm
Parents of youth (8-18YO) diagnosed with T1D.
Overall Study
STARTED
24
21
Overall Study
COMPLETED
3
0
Overall Study
NOT COMPLETED
21
21

Reasons for withdrawal

Withdrawal data not reported

Baseline Characteristics

Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Primary Analysis Arm
n=24 Participants
Youth (8-21 YO) diagnosed with T1D
Parent Arm
n=21 Participants
Parents of youth (8-18 YO) diagnosed with T1D
Total
n=45 Participants
Total of all reporting groups
Age, Categorical
<=18 years
3 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
3 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Age, Categorical
Between 18 and 65 years
21 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
21 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Age, Categorical
>=65 years
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Sex: Female, Male
Female
10 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
10 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Sex: Female, Male
Male
14 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
14 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Ethnicity (NIH/OMB)
Hispanic or Latino
3 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
3 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Ethnicity (NIH/OMB)
Not Hispanic or Latino
17 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
17 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Ethnicity (NIH/OMB)
Unknown or Not Reported
4 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
4 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
American Indian or Alaska Native
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
Asian
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
Native Hawaiian or Other Pacific Islander
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
Black or African American
4 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
4 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
White
19 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
19 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
More than one race
1 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
1 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
Race (NIH/OMB)
Unknown or Not Reported
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).
0 Participants
n=24 Participants • Only parent data was collected for Secondary Outcomes 16, 18, and 21. Parents only completed the Hypoglycemic Fear Scale II for Parents (HFS-P).

PRIMARY outcome

Timeframe: Up to 365 days +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Minutes per Day of MVPA

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 90 days +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Rate of hospitalization for diabetic ketoacidosis

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 180 days +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Rate of hospitalization for diabetic ketoacidosis

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 365 +-30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Rate of hospitalization for diabetic ketoacidosis

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Over 90, 180, and 365 +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Time where blood glucose is in an appropriate range (and other glucose measurements)

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 90 +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

machine learning models to predict change in HbA1c, DKA admissions, and change in Time in Range

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 180 +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

machine learning models to predict change in HbA1c, DKA admissions, and change in Time in Range

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: 365 +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

machine learning models to predict change in HbA1c, DKA admissions, and change in Time in Range

Outcome measures

Outcome data not reported

PRIMARY outcome

Timeframe: Up to 365 days +- 30 days

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Minutes of Sleep per Day

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 0 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Self-reported physical activity via the International Physical Activity Questionnaire Short Form (IPAQ-SF), no min or max, recording the amount of time spent in MVPA in the past week, higher amounts are better.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Self-reported physical activity via the International Physical Activity Questionnaire Short Form (IPAQ- SF), no min or max, recording the amount of time spent in MVPA in the past week, higher amounts are better.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Self-reported physical activity via the International Physical Activity Questionnaire Short Form (IPAQ-SF), no min or max, recording the amount of time spent in MVPA in the past week higher amounts are better.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 0 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale (HFS-II) min 0 max 132, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale (HFS-II) min 0 max 132, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale (HFS-II) min 0 max 132, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 0 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale II for Parents (HFS-P) min 0 max 143, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 6 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale II for Parents (HFS-P) min 0 max 143, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Hypoglycemic Fear Scale II for Parents (HFS-P) min 0 max 143, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Between 0, 6, and 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Change in self reported physical activity levels via self-report with the IPAQ survey no min or max, recording the amount of time spent in MVPA in the past week, higher amounts are better.

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Between 0, 6, and 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Change in how participants feel about episodes of hypoglycemia measured via the Hypoglycemic Fear Scale II (HFS-II) min 0 max 132, higher scores are a worse outcome

Outcome measures

Outcome data not reported

SECONDARY outcome

Timeframe: Between 0, 6, and 12 months

Population: Study terminated before analysis took place, due to slow enrollment and unexpected termination the little data collected could not be analyzed. There is no future plan to analyze the data.

Change in how parents feel about episodes of hypoglycemia in their children wearing the Garmin physical activity tracker via the Hypoglycemic Fear Scale II for Parents (HFS-P) min 0 max 143, higher scores are a worse outcome

Outcome measures

Outcome data not reported

Adverse Events

Primary Analysis Arm

Serious events: 0 serious events
Other events: 3 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Primary Analysis Arm
n=24 participants at risk
Youth (8-21 YO) diagnosed with T1D.
Skin and subcutaneous tissue disorders
Rash
12.5%
3/24 • Number of events 3 • 1 year
Only adverse events were monitored for youth as parents only completed Hypoglycemic Fear Scale II for Parents (HFS-P) for the study.

Additional Information

Priscilla Connell

Children's Mercy Research Institute

Phone: 8166014543

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place